{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:46:03Z","timestamp":1780490763205,"version":"3.54.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,15]]},"DOI":"10.2146\/ajhp110374","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T16:16:26Z","timestamp":1346343386000},"page":"1551-1557","source":"Crossref","is-referenced-by-count":33,"title":["Vilazodone: A novel antidepressant"],"prefix":"10.1093","volume":"69","author":[{"given":"Elizabeth","family":"Choi","sequence":"first","affiliation":[{"name":"Northport Veterans Affairs Medical Center, Northport, NY; at the time of writing, she was a Pharm.D. candidate, School of Pharmacy, University of Connecticut (UC), Storrs."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Zmarlicka","sequence":"additional","affiliation":[{"name":"School of Pharmacy, UC, Storrs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan J.","family":"Ehret","sequence":"additional","affiliation":[{"name":"School of Pharmacy, UC, Storrs"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041204013096700_b1-0691551","first-page":"317","volume-title":"Diagnostic and statistical manual of mental disorders, 4th edition, text revision","author":"American Psychiatric Association","year":"2000"},{"key":"2019041204013096700_b2-0691551","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kesseler","year":"2005","journal-title":"Arch Gen Psychiatry."},{"key":"2019041204013096700_b3-0691551","unstructured":"Department of Health and Human Services. Mental health: a report of the surgeon general\u2014executive summary. www.surgeongeneral.gov\/library\/mentalhealth\/home.html (accessed 2011 Jun 10)."},{"key":"2019041204013096700_b4-0691551","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1176\/ajp.2007.164.2.201","article-title":"STAR*D: what have we learned?","volume":"164","author":"Rush","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2019041204013096700_b5-0691551","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry."},{"key":"2019041204013096700_b6-0691551","first-page":"52","article-title":"Top 200 drugs of 2010","volume":"5","author":"Bartholow","year":"2011","journal-title":"Pharmacy Times."},{"key":"2019041204013096700_b7-0691551","first-page":"252","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celeda","year":"2004","journal-title":"J Psychiatry Neurosci."},{"key":"2019041204013096700_b8-0691551","first-page":"84","article-title":"Vilazodone for major depressive disorder","volume":"10","author":"Kalia","year":"2011","journal-title":"Curr Psychiatry."},{"key":"2019041204013096700_b9-0691551","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1016\/j.bmc.2004.07.014","article-title":"Dual 5-HT1A agonists and 5-HT reuptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity","volume":"12","author":"Heinrich","year":"2004","journal-title":"Bioorg Med Chem."},{"key":"2019041204013096700_b10-0691551","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1021\/jm040793q","article-title":"Synthesis and structure-activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors","volume":"47","author":"Heinrich","year":"2004","journal-title":"J Med Chem."},{"key":"2019041204013096700_b11-0691551","volume-title":"Viibryd (vilazodone hydrochloride) package insert","year":"2011"},{"key":"2019041204013096700_b12-0691551","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0306-4522(91)90128-B","article-title":"5-Hydroxytryp-tamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex","volume":"40","author":"Araneda","year":"1991","journal-title":"Neuroscience."},{"key":"2019041204013096700_b13-0691551","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0165-6147(00)01682-5","article-title":"How does pindolol improve antidepressant action?","volume":"22","author":"Artigas","year":"2001","journal-title":"Trends Pharmacol Sci."},{"key":"2019041204013096700_b14-0691551","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.102.034280","article-title":"Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2- carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor partial agonist","volume":"302","author":"Page","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"2019041204013096700_b15-0691551","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","article-title":"Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin re-uptake inhibitor, vilazodone","volume":"510","author":"Hughes","year":"2005","journal-title":"Eur J Pharmacol."},{"key":"2019041204013096700_b16-0691551","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2005.05.039","article-title":"Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus","volume":"517","author":"Roberts","year":"2005","journal-title":"Eur J Pharmacol."},{"key":"2019041204013096700_b17-0691551","first-page":"19","article-title":"Vilazodone: another novel atypical antidepressant drug","volume":"49","author":"Howland","year":"2011","journal-title":"J Psychosoc Nurs."},{"key":"2019041204013096700_b18-0691551","unstructured":"Forest Pharmaceuticals. Viibryd(vilazodone hydrochloride) Tablets. www.frx.com\/pi\/viibryd_pi.pdf (accessed 2012 Jul 6)."},{"key":"2019041204013096700_b19-0691551","volume-title":"Vilazodone pharmacokinetics in subjects with mild to moderate renal impairment","author":"Alcorn"},{"key":"2019041204013096700_b20-0691551","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0969-8051(00)00120-7","article-title":"Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635","volume":"27","author":"Rabiner","year":"2000","journal-title":"Nucl Med Biol."},{"key":"2019041204013096700_b21-0691551","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.08m04637","article-title":"Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Rickels","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"2019041204013096700_b22-0691551","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4088\/JCP.10m06596","article-title":"A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder","volume":"72","author":"Khan","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"2019041204013096700_b23-0691551","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/17410541.6.2.217","article-title":"Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression","volume":"6","author":"Rickels","year":"2009","journal-title":"Pers Med."},{"key":"2019041204013096700_b24-0691551","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1517\/13543780903286396","article-title":"Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression","volume":"18","author":"Khan","year":"2009","journal-title":"Expert Opin Investig Drugs."},{"key":"2019041204013096700_b25-0691551","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol."},{"key":"2019041204013096700_b26-0691551","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry."},{"key":"2019041204013096700_b27-0691551","volume-title":"Clinical global impressions. ECDEU assessment manual for psycho-pharmacology","author":"Guy","year":"1976"},{"key":"2019041204013096700_b28-0691551","doi-asserted-by":"crossref","article-title":"A 1-year open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder","author":"Robinson","DOI":"10.1097\/JCP.0b013e31822c6741"},{"key":"2019041204013096700_b29-0691551","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/11204760-000000000-00000","article-title":"Escitalopram: a review of its use in the management of major depressive disorder in adults","volume":"24","author":"Garnock-Jones","year":"2010","journal-title":"CNS Drugs."},{"key":"2019041204013096700_b30-0691551","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1755-5949.2008.00067.x","article-title":"Vilazodone: a 5-HT1A receptor agonist\/serotonin transporter inhibitor for the treatment of affective disorder","volume":"15","author":"Dawson","year":"2009","journal-title":"CNS Neurosci Ther."},{"key":"2019041204013096700_b31-0691551","first-page":"51","article-title":"Buspirone in clinical practice","volume":"51","author":"Rickels","year":"1990","journal-title":"J Clin Psychiatry."},{"key":"2019041204013096700_b32-0691551","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4088\/JCP.v62n0608","article-title":"Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study","volume":"62","author":"Appleberg","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"2019041204013096700_b33-0691551","volume-title":"Thomson Reuters Micromedex Clinical Evidence Solutions","year":"2011"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/18\/1551\/28361925\/ajhp1551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:03:33Z","timestamp":1555113813000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/18\/1551\/5111963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,15]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,9,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110374","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,9,15]]},"published":{"date-parts":[[2012,9,15]]}}}